Pasteurella haemolytica in cattle produces fibrinohemorrhagic pleuropneumonia characterized by extensive pulmonary microvascular thrombosis and parenchymal necrosis. The purpose of this in vitro study was to determine if P. haemolytica lipopolysaccharide (LPS) promotes vascular thrombosis by inducing a procoagulant state in vascular endothelial cells. After treatment of confluent monolayers of bovine pulmonary artery endothelial cells with various concentrations of either P. haemolytica LPS or Escherichia coli LPS, the procoagulant activity of the endothelial cells was determined using a chromogenic assay dependent on cellular tissue factor expression. The LPS treatment induced significant increases in cellular tissue factor expression in a LPS concentration-and time-dependent manner. Highest levels of tissue factor were present at 22 hours after treatment, although high LPS concentrations induced moderate tissue factor levels at 5 hours after treatment. Interleukin-1 also induced tissue factor expression in endothelial cells and enhanced the LPS-induced effects. This interleukin-1 effect could be diminished by concurrent use of an interleukin-1 receptor antagonist. These results demonstrate that LPS and cytokine promotion of a procoagulant state in endothelial cells occurs in vitro. Similar mechanisms may play a role in P. haernolytica-mediated pulmonary vascular thrombosis.
Bovine pneumonic pasteurellosis, caused by Pasteurella haemolytica (serotype 1, biotype A), is characterized by airway accumulations of leukocytes, fibrin, edema, and hemorrhage; microvascular thrombosis; extensive parenchymal necrosis; and fibrinous pleur i t i~.~,~~,~~,~~ The extensive tissue necrosis associated with the disease has been attributed to microvascular thrombosis,22 but little work has been done to determine mechanisms of intravascular coagulation induction.
Treatment of cultured human vascular endothelial cells (EC) with various cytokines, bacterial lipopolysaccharide (LPS), or nonspecific cell activators promotes increased cell expression of tissue factor, also ~a d e .~J~ In addition, loss of EC and exposure of the underlying basement membrane results in activation of Hageman factor (factor XII) and the intrinsic coagulation cascade. 26 The purpose of this study was to determine if P. haemolytica LPS promoted procoagulant activity in bovine EC. In addition, because the macrophage-derived cytokines, interleukin-1 and tumor necrosis factor, are important in P. haemolytica-induced EC tox-i~i t y ,~' ,~~ an investigation was also conducted to determine if interleukin-1 promoted a procoagulant state in EC.
Materials and Methods
known as thromboplastin or factor III.4,", '8,33 Tissue factor is a cell membrane-associated glycoprotein that initiates the extrinsic coagulation cascade by acting as a cofactor with clotting factor ~1 1 . 3 Factor VII, calcium ions, phospho~ipid, and tissue factor collectively lead to activation of factor X, conversion of prothrombin to thrombin, and fibrin f~r m a t i o n .~ production of prostacyclin, thrombomodulin, and sev-era1 other However, Won stimulation or injury, EC produce Procoagulant Proteins or prostaglandins that can initiate the extrinsic coagulation cas-Pasteurella haemolytica (biotype A, serotype 1; obtained from Richard Corstvet, Baton Rouge, LA) lipopolysaccharide (Lps) was extracted by a Phenol-water method as Previously described." The LPS preparation contained 2,000 endotoxin unitdpg as determined by a chromogenic Limulus assay (Whittaker MA Bioproducts, Walkersville, MD). Escherichia coli LPS (serotype 055:B5; Sigma, St. Louis, MO) used in this study contained 11,000 endotoxin unitdpg as nant bovine interleukin-1 -p (30, Tissue factor (thromboplastin) activity determined by either the chromogenic assay (optical density) (0) or the prothrombin time assay (l/second x lo3) (W). Note the similar response in both assay systems that is dependent on the tissue factor concentration. Coefficient analysis statistically verified correlation of tissue factor concentration for both the chromogenic and prothrombin time assay ( r = 0.98, P < 0.02).
Primary endothelial cell (EC) cultures were established from adult bovine pulmonary arteries as previously d e~c r i b e d . '~ The cells were identified as EC by typical cobblestone morphology and the presence of factor VIII-related antigen, as described previously.'? The EC used in all experiments were of the same cell line (ENS-2) and less than passage 20. The EC were maintained in Dulbecco's Modified Eagle Medium (DMEM) (Whittaker MA Bioproducts) plus 10% heat inactivated fetal bovine serum (lot no. 1 1 1 1843, HyClone Laboratories, Logan, UT) and 2 m M L-glutamine (Flow Laboratory, Irvine, CA).
The prothrombin time of rabbit brain tissue factor (Johnson and Johnson Co., Raritan, NJ) was measured by a modified prothrombin time assay.l0 The tissue factor was diluted in 30 m M calcium chloride saline that had been prewarmed to 37 C; platelet-poor bovine plasma (PPP) was also prewarmed for 3 minutes at 37 C. The modified prothrombin time, determined with a fibrometer (BBL Fibrosystem), was the time required to clot 0.1 ml PPP with 0.2 ml diluted tissue factor. Tissue factor expression of the EC was quantitated with a colorimetric assay3" based on digestion of chromogenic S-2222 substrate (Kabi Pharmaceuticals, Franklin, OH) by activated factor X, dependent on generation of EC tissue factor. Endothelial cells were plated at 40,000 cells/well in 96-well flatbottom tissue culture plates. Various concentrations of P.
haetnolytica LPS and E. coli LPS were added to the confluent EC. Following 37 C incubation for specified time periods, plates were washed twice with phenol red-free DMEM, followed by addition of 100 Fl/well of phenol red-free DMEM containing 200 fig/ml of S-2222 and 1 unit factor VII/ml of a coagulation factor concentrate consisting of factors 11, VII, IX, and X (Proplex T, Travenol Labs, Glendale, CA). After a 60-minute incubation at 37 C, the optical density at 405 n m wavelength was quantitated using a Bio-Tek microplate reader. Various dilutions of rabbit brain tissue factor were included in assays as positive controls. Negative controls consisted of wells without LPS treatment, and blank wells consisted ofwells without Proplex T. Each treatment variable was done in triplicate, and the experiments were repeated to confirm results.
To visually detect tissue factor on EC, an anti-bovine tissue factor antibody and commercially available avidin-biotinimmunoperoxidase immunocytochemical system were used. Monolayers of EC cells, established on chamber slides (Lab-Tek, Nunc, Naperville, IL), were treated with 100 n d m l of P. haemo/.vtica LPS for 8 hours at 37 C. The cells were then fixed with acetone for 1 minute, washed twice with phosphate-buffered saline (PBS), treated with 1 : 100 dilution of rabbit anti-bovine tissue factor IgC (20 pg/ml; provided by R. Bach, New York, NY) for 60 minutes, washed twice with PBS, treated with 1 : 100 dilution of anti-IgC antibody conjugated to biotin for 60 minutes (Zymed, San Francisco, CA), followed by avidin-peroxidase and then 3-amino-9-ethylcarbazol substrate. Negative controls included untreated EC and LPS-treated EC without primary antibody.
Statistical analysis of tissue factor expression of the different variables was done using Duncan's multiple range test ( P < 0.05). Coefficient analysis was used to determine correlation of the prothrombin time and colorimetric assays to tissue factor concentration.
Results

Correlation of prothrombin time assay and colorimetric assay
Log dilutions of rabbit brain tissue factor were measured in both the prothrombin time assay (PTA) and the chromogenic tissue factor assay to verify the sensitivity and specificity of the chromogenic assay ( Fig.  1 ). The chromogenic assay resulted in a tissue factor dose response very similar to that of the conventional PTA. Coefficient analysis demonstrated correlation of tissue factor concentration to either PTA or chromogenic assay (r = 0.98, P < 0.02).
Kinetics of lipopolysaccharide-induced tissue factor expression
Tissue factor expression was determined in endothelial cells (EC) at 2, 5 , and 22 hours following the addition of either Pasteurella haemolytica lipopolysaccharide (LPS) ( Fig. 2A ) or Escherichia coli LPS (Fig.  2B ). Although very little tissue factor was evident at 2 hours, within 5 hours after treatment both types of LPS induced significant tissue factor expression in a dose-dependent manner. High tissue factor levels were evident at 1 ng/ml levels for E. coli LPS (0.329 optical density [OD]) and 10 nglml for P. haemolytica (0.290 OD) LPS at 22 hours post-treatment (PT); however, tissue factor expression decreased at LPS doses of 100 nglml and 1,000 nglml for both types of LPS by 22 hours PT. Use of the immunohistochemical method to verify tissue factor expression on LPS-treated EC was successful. The EC treated with 100 ng/ml P. haemolytica LPS demonstrated characteristic orange cy- toplasmic staining (data not shown), whereas untreated EC were negative.
Interaction of LPS and interleukin-1
To verify if interleukin-1 (IL-1) increased the effect of LPS on EC tissue factor expression, EC were treated with IL-1 alone or in combination with LPS. At 2 and 5 hours following only IL-1 treatment, the tissue factor levels were negligible (< 0.05 OD); however at 22 hours after treatment, a dose-dependent increase of tissue factor was evident (Fig. 3) . In another experiment, IL-1 ( 5 unitdwell) was added to EC 16 hours prior to LPS addition. The combined IL-1 and P. haemolytica LPS or E. coli LPS treatment produced an approximately twofold enhancement of tissue factor expression at 5 hours after LPS treatment, as compared with treatment with IL-1 or LPS alone (Fig. 4) .
To confirm the importance of IL-1 in EC tissue factor induction, some EC were treated with IL-1 receptor antagonist (IL-Ira) and 5 units/well of IL-1 for 16 hours, and other cells were treated with only IL-lra. Lipopolysaccharide was added to IL-1 ra-only-treated cells and incubated an additional 5 hours. The IL-Ira significantly decreased tissue factor expression promoted by IL-1 in a dose-related response; however, IL-lra had no inhibitory effect on LPS-induced tissue factor expression at 5 hours PT (Fig. 5 ). Interleukin-1 receptor antagonist (nwell) Fig. 5 . Tissue factor expression on bovine endothelial cell monolayers determined by a chromogenic assay. The cells were treated initially with the indicated concentrations of interleukin-1 receptor antagonist (IL-Ira) followed by either Pastewella haemo/.vtica LPS ( I00 ng/ml) (0) or Eschcrichia coli LPS (100 ng/ml) (B). Recombinant bovine interleukin-1-0 (IL-1) was added to one group of IL-1 ra treated cells (A). The tissue factor concentrations were determined a t 5 hours following LPS treatment and at 22 hours following IL-1 treatment. Data represent the mean and standard error of the mean of triplicates.
Discussion
The results of this study clearly demonstrate enhanced tissue factor activity in bovine endothelial cells (EC) following treatment with either Pasteureffa haemolytica or Escherichia coli lipopolysaccharide (LPS) and are similar to results of previous studies using human umbilical vein endothelial cell (HUVEC) and E. cofi LPS.4,11,18.33 However, unlike HUVEC studies, extended 22-hour incubation of bovine EC with high concentrations of LPS resulted in low levels of tissue factor expression. This difference is probably due to LPS-mediated toxicity of bovine EC and resultant cell detachment. As previously reported,8,'6,20 only minimal cytotoxicity of bovine EC occurs 2 or 5 hours following LPS treatment (1 .O-1,000 ng/ml); however, by 22 hours post-treatment (PT) maximum cytotoxicity of bovine EC occurs.8 In the present study, bovine EC death was not monitored with a cytotoxicity assay, but the LPS-treated cells were observed with phase microscopy. At 5 hours PT, the monolayers demonstrated only mild cellular contraction, whereas at 22 hours PT, most cells were detached and/or fragmented (data not shown). Although HUVEC are activated by LPS, there is no observed cytotoxicity, even at high LPS concentrations.21 Both P. haemolytica and E. coli LPS had a similar effect on bovine EC tissue factor production, which was similar to effects in previous studies of bovine EC cytotoxicity following treatment with both types of LPS8 The E. coli LPS was slightly more potent than the P. haemolytica LPS in inducing increased tissue factor expression, probably because of the higher endotoxin units per milliliter of the E. cofi LPS preparation versus the P. haemolytica LPS. The reason for potency difference between the two LPS preparations was not apparent because the LPS preparations were not chemically characterized and LPS-binding studies were not performed on bovine EC. However, the biological activity of LPS in the chromogenic Limulus lysate assay may be related to a somewhat different mechanism than LPS binding to bovine EC, resulting in induction of tissue factor expression.
The expression of tissue factor on EC is an important indicator of a procoagulant state and initiation of the coagulation cascade.12 Tissue factor, also known as thromboplastin or factor 111, is a glycoprotein produced and expressed on the surface of several mammalian cells, including fibroblasts, EC, and macrophages/mon~cytes.~ Tissue factor is important in initiating the extrinsic coagulation pathway, acting as a cofactor for factor VII. The factor VII and tissue factor complex, in concert with calcium ions and phospholipid, activates factor X, resulting in thrombin and eventual fibrin generation. Although no tissue factor genetic deficiencies have been identified, bleeding disorders associated with a factor VII deficiency imply the importance of tissue factor in maintaining bleeding homeo~tasis.~
The EC is an important regulator of coagulation homeostasis, possessing inherent anticoagulation properties unless damaged or activated.12 If HUVEC are treated with LPS, interleukin-1 (IL-l), or tumor necrosis factor (TNF'), a procoagulant activation state results due to enhanced tissue factor expression and increased tissue plasminogen activator production. 4,7,13.25 In addition, LPS promotes diminished anticoagulation properties of HUVEC that are normally present, such as thrombomodulin or tissue plasminogen activator inhibitor.l2.I8
In addition to direct LPS-mediated effects on EC during bacterial disease, LPS also stimulates macrophage/monocyte populations to secrete proinflammatory cytokines, such as IL-1 and TNF. 14.19 The enhanced expression of bovine EC tissue factor expression following IL-1 treatment in this study is similar to that in previous reports of HUVEC treated with IL-1 or TNF.6,7,25 However, IL-1 -stimulated tissue factor levels in bovine EC were maximal at 22 hours following treatment, whereas in a previous study tissue factor levels in HUVEC were maximal at 4 hours following treatment.5 Bovine and human EC may vary in the induction kinetics of tissue factor expression, or perhaps cellular response is influenced by the cytokine source. In the present study, recombinant bovine IL-1-p was used, whereas in the previous study,5 human IL-1 purified from stimulated human monocyte cultures was used.
The combination treatment of IL-1 and either E. coli or P. haemolytica LPS produced an additive effect, resulting in higher levels of tissue factor in EC treated with both IL-1 and LPS versus LP alone. Previous reports have demonstrated that LPS, IL-1, and TNF may similarly activate HUVEC and have additive and that either IL-1 or TNF enhances LPSmediated toxicity of bovine EC in an additive manner. 27 Also, HUVEC-human monocyte cocultures have much higher tissue factor expression following LPS stimulation than do HUVEC alone,33 presumably because of monocyte-secreted IL-1.
Attempts to inhibit IL-1 -mediated tissue factor expression of bovine EC in this study using IL-1 receptor antagonist (IL-1 ra) were successful. However, the IL-Ira did not have any inhibitory effect on LPS promotion of EC tissue factor. Interleukin-1 receptor antagonist is a naturally occurring substance secreted by macrophages as a downregulator of acute inflammat i~n .~J~ Recently, IL-lra has been shown effective in alleviating clinical signs and mortality in mice and rabbits treated with lethal doses of E. coli LPS.1,31. 32 Recently, IL-lra has also been used to successfully decrease IL-1 -enhanced LPS cytotoxicity in bovine EC. 27 Collectively, these in vitro results suggest that inhibition of IL-1 biological actions in vivo may decrease LPS-mediated vascular damage and thrombosis in cattle.
Although the pathogenesis of bovine pulmonic pasteurellosis is not completely defined, a recent review suggests that P. haemolytica elicits several factors that are important in initiating inflammation and subsequent tissue damage in the lung. 36 Pasteurella haemolytica LPS is directly toxic to bovine ECs,20 and, as shown in this study, promotes a procoagulant state in EC. A recent study has demonstrated immunohistochemically that LPS is present within the alveolar capillary EC cytoplasm during active P. haemolytica inf e~t i o n ,~~ further supporting the importance of LPS in disease progression. Pasteurella haemolytica LPS is a very important factor in the dramatic microvascular thrombosis and parenchymal necrosis evident during most P. haemolytica pulmonary infection. In the bovine lung, LPS may activate EC to a procoagulant state or be directly toxic to the EC, resulting in EC loss and exposure of underlying fibroblast tissue factor or basement membrane collagen. In addition, LPS-mediated macrophage-secreted IL-1 and TNF may enhance the LPS effect on EC. Neutralizing the biological activity of LPS or modulating the inflammatory process that results from LPS in the lung may help control the progression of bovine pulmonary pasteurellosis.
